Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $16.00

SAB Biotherapeutics (NASDAQ:SABS) had its target price upped by equities researchers at Chardan Capital from $14.00 to $16.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s target price would indicate a potential upside of 337.16% from the stock’s current price.

A number of other analysts have also issued reports on the stock. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday. Rodman & Renshaw restated a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Finally, Jefferies Financial Group assumed coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.88.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $3.66 on Wednesday. The company has a 50 day simple moving average of $3.69 and a 200-day simple moving average of $3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The firm has a market capitalization of $279.84 million, a price-to-earnings ratio of -1.73 and a beta of 0.54. SAB Biotherapeutics has a 52-week low of $1.65 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities research analysts predict that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. acquired a new position in SAB Biotherapeutics during the first quarter valued at approximately $29,000. State of Wyoming bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $34,000. State Street Corp bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $49,000. Fifth Lane Capital LP bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.